Patents by Inventor Scott Crowe

Scott Crowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12570736
    Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-7R binding polypeptide.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: March 10, 2026
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Lurdes Duarte, Keith Ray
  • Patent number: 12559552
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: February 24, 2026
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Marion Cubitt, Tim Carlton, Luana Maggiore, Lurdes Duarte, Kevin Roberts, Mike West
  • Publication number: 20250388655
    Abstract: There is provided inter alia a construct suitable for oral administration comprising a first polypeptide and a second polypeptide connected by a labile peptide linker, wherein the labile peptide linker is labile to one or more proteases present in the intestinal tract and wherein the first and second polypeptides are substantially resistant to said one or more proteases.
    Type: Application
    Filed: January 16, 2025
    Publication date: December 25, 2025
    Inventors: Scott CROWE, Mike WEST, Kevin ROBERTS
  • Publication number: 20250277043
    Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.
    Type: Application
    Filed: January 8, 2025
    Publication date: September 4, 2025
    Inventors: Scott CROWE, Mike WEST, Kevin ROBERTS, Tim CARLTON, Luana MAGGIORE, Marion CUBITT, Lurdes DUARTE, Martyn SYMMONS, Keith RAY
  • Patent number: 12247079
    Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: March 11, 2025
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Lurdes Duarte, Martyn Symmons, Keith Ray
  • Patent number: 12234279
    Abstract: There is provided inter alia a construct suitable for oral administration comprising a first polypeptide and a second polypeptide connected by a labile peptide linker, wherein the labile peptide linker is labile to one or more proteases present in the intestinal tract and wherein the first and second polypeptides are substantially resistant to said one or more proteases.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: February 25, 2025
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Mike West, Kevin Roberts
  • Patent number: 12173054
    Abstract: Described herein is a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue. The polypeptides of this disclosure possess increased intestinal stability relative to a corresponding polypeptide not having the histidine substitutions.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: December 24, 2024
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton
  • Patent number: 12098197
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: September 24, 2024
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Tim Carlton, Marion Cubitt, Kevin Roberts, Luana Maggiore, Mike West, Keith Ray
  • Publication number: 20240277864
    Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-6R binding polypeptide.
    Type: Application
    Filed: April 26, 2023
    Publication date: August 22, 2024
    Inventors: Scott CROWE, Kevin ROBERTS, Tim CARLTON, Luana MAGGIORE, Marion CUBITT, Mike WEST, Keith RAY
  • Publication number: 20230287098
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Application
    Filed: April 18, 2023
    Publication date: September 14, 2023
    Inventors: Scott CROWE, Mike WEST, Kevin ROBERTS, Tim CARLTON, Luana MAGGIORE, Marion CUBITT, Keith RAY
  • Patent number: 11684677
    Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-6R binding polypeptide.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: June 27, 2023
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Mike West, Keith Ray
  • Patent number: 11667719
    Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: June 6, 2023
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Lurdes Duarte, Martyn Symmons, Keith Ray
  • Publication number: 20230143091
    Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-7R binding polypeptide.
    Type: Application
    Filed: June 19, 2020
    Publication date: May 11, 2023
    Inventors: Scott CROWE, Mike WEST, Kevin ROBERTS, Tim CARLTON, Luana MAGGIORE, Marion CUBITT, Lurdes DUARTE, Keith RAY
  • Patent number: 11623952
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: April 11, 2023
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Marion Cubitt, Tim Carlton, Luana Maggiore, Lurdes Duarte, Kevin Roberts, Mike West
  • Publication number: 20230056445
    Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.
    Type: Application
    Filed: June 19, 2020
    Publication date: February 23, 2023
    Inventors: Scott CROWE, Mike WEST, Kevin ROBERTS, Tim CARLTON, Luana MAGGIORE, Marion CUBITT, Lurdes DUARTE, Martyn SYMMONS, Keith RAY
  • Publication number: 20220380475
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Application
    Filed: March 18, 2022
    Publication date: December 1, 2022
    Inventors: Scott Crowe, Tim Carlton, Marion Cubitt, Kevin Roberts, Luana Maggiore, Mike West, Keith Ray
  • Publication number: 20220363769
    Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.
    Type: Application
    Filed: May 24, 2022
    Publication date: November 17, 2022
    Inventors: Scott CROWE, Mike WEST, Kevin ROBERTS, Tim CARLTON, Luana MAGGIORE, Marion CUBITT, Lurdes DUARTE, Martyn SYMMONS, Keith RAY
  • Publication number: 20220332810
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.
    Type: Application
    Filed: May 20, 2022
    Publication date: October 20, 2022
    Inventors: Scott CROWE, Marion CUBITT, Tim CARLTON, Luana MAGGIORE, Lurdes DUARTE, Kevin ROBERTS, Mike WEST
  • Publication number: 20220242945
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.
    Type: Application
    Filed: June 19, 2020
    Publication date: August 4, 2022
    Inventors: Scott CROWE, Marion CUBITT, Tim CARLTON, Luana MAGGIORE, Lurdes DUARTE, Kevin ROBERTS, Mike WEST
  • Patent number: 11401327
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: August 2, 2022
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Tim Carlton, Marion Cubitt, Kevin Roberts, Luana Maggiore, Mike West, Keith Ray